anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ambrisentan
Trial phase: Phase 3
ATC code: C02KX02 | C02KX52
SMILES: COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Treatment-naive Group 1 Pulmonary Arterial Hypertension patients with Porto-pulmonary Hypertension with Child-Pugh class A/B were administered with ambrisentan for 24 weeks, followed by a long-term extension (24-28 weeks).
Eligibility criteria:
Inclusion Criteria:

Subjects need to fulfill all of the following 4 criteria:

Evidence of portal hypertension (by hemodynamic measurement, or by Doppler flow of portal circulation, or by clinical evidence of portal hypertension such as esophageal or gastric varices, as evidenced by prior upper endoscopy).

Evidence of pulmonary arterial hypertension by right heart catheterization (all three criteria need to be present) Right heart catheterization may have been performed up to 30 days prior to screening

Mean PAP (pulmonary artery pressure) >25 mm Hg, and
PVR (pulmonary vascular resistance) >240 dynes/s/cm5, and
TPG (transpulmonary gradient = meanPAP -PAWP) >12 mm Hg
Baseline AST, ALT < 5 times the upper limit of normal, total Bili < 3.0 mg/dl, and mild liver impairment with Child -Pugh class A or B
Ages 18 years and above

Exclusion Criteria:

Presence of any other etiology of pulmonary arterial hypertension (HIV, connective tissue disease, sickle cell, left heart failure, chronic thromboembolic PH, etc)
Treatment with prostacyclins, other ERAs, or PDE5 inhibitors within 30 days of enrollment.
Moribund state or anticipated death within 1 month.
AST or ALT ≥ 5 times upper limit of normal
Total bilirubin ≥ 3.0 mg/dl
Significant lung disease (obstructive lung disease with FEV1 < 1L, or FEV1/FVC <50%; or restrictive lung disease with Total Lung Capacity < 60% predicted). PFTs may have been performed up to 6 months prior to enrollment.
Pregnancy
Age <18 years
Child -Pugh class C
Intervention: TERIPARATIDE
Trial phase: Phase 2
ATC code: H05AA02
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Teriparatide alone with sham vibration

Teriparatide: 20 ug daily over 12 months
Eligibility criteria:
Inclusion Criteria:

Age >21 years (must have closed epiphyses; PTH contraindicated if epiphyses open)

Both males and females
SCI with inability to ambulate independently
Capable of positioning to have DXA performed
Low bone mass at the total hip by DEXA (Z score < 1.5; T score < 2.5 or T score <-2.0 plus preexisting fragility fracture)
Capable of reading and understanding informed consent document
Able to self-administer teriparatide or have someone in the family who can do so
No known endocrinopathies
Normal TSH levels
Normal 25-OH vitamin D levels (> 30ng/ml)
Normal calcium levels
Normal renal function (creatinine <2.0mg/dl)
Able to return for all follow-up visits

Exclusion Criteria:

Surgical or other intervention resulting in metal or anatomy precluding obtaining DXA measurements (e.g., cardiac pacemakers, ferromagnetic implants or brain aneurysm clips).

Had had an allergic reaction to Teriparatide (FORTEO) or one of its ingredients.
Have Paget's disease of the bone
Have unexplained high levels of f alkaline phosphatase in blood
Any active Gastrointestinal condition that results in malabsorption
History of presence of alcoholism or drug abuse within the 2 years prior to study screening
Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study
History of malignancy. Patients having had basal cell carcinomas successfully removed will be allowed to enroll in the protocol.
History of radiation therapy
Unable to self-administer PTH or have it administered
Elevated liver function tests >2x normal
Currently being prescribed anti-convulsants
Currently being prescribed glucocorticoids, other than inhaled glucocorticoids
Currently being prescribed any bone-active agents, including any bisphosphonate, raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or strontium-containing compounds. Bisphosphonate use will be allowed up the time of initiation of study medication but not during the dosing with study medication.
Previous history of PTH use
Pregnant, planning to become pregnant, or lactating
Intervention: 3-Thiaglutaryl-Coa
Trial phase: Not Applicable
SMILES: CC(C)(COP(=O)(O)OP(=O)(O)OCC1OC(n2cnc3c(N)ncnc32)C(O)C1OP(=O)(O)O)C(O)C(=O)NCCC(=O)NCCSC(=O)CSCC(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 99
Group description: Allocated to control group (n = 100)

Received allocated intervention (n = 99)
Did not receive allocated intervention: change operation (n = 1)
Eligibility criteria:
Inclusion Criteria:

age > 15 years
cardiac surgery with cardiopulmonary bypass

Exclusion Criteria:

active infection
insulin allergy
off-pump cardiopulmonary bypass procedures
Intervention: Simvastatin
Trial phase: Phase 2
ATC code: A10BH51 | C10AA01 | C10BA02 | C10BA04 | C10BX01 | C10BX04
SMILES: CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 28
Group description: Participants in this arm received Simvastatin 20 mg twice daily and Vitamin D3 1000 IU twice daily for 6 months.
Eligibility criteria:
Inclusion Criteria:

Age 18 years or older
Have had migraines for at least 3 years
Have between 4 and 15 migraines a month
Able to speak and read the English language

Exclusion Criteria:

Women who are pregnant or nursing, or planning on becoming pregnant in the next 10 months
Individuals who have a had a heart attack, stroke, peripheral artery disease, atherosclerotic aortic disease, carotid artery disease, or diabetes
individuals at high risk for cardiovascular disease
Intervention: Ceralifimod
Trial phase: Phase 2
SMILES: CCCc1ccc(COc2ccc3c(c2)CCC(CN2CC(C(=O)O)C2)=C3C)c(OC)c1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Subjects who were administered with ONO-4641 at a dose of 0.15 mg in the core study were administered with ONO-4641 at a dose of 0.15 mg once daily in the extension study for a duration of 225 weeks.
Eligibility criteria:
Inclusion Criteria:

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Exclusion Criteria:

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer
Intervention: Ceralifimod
Trial phase: Phase 2
SMILES: CCCc1ccc(COc2ccc3c(c2)CCC(CN2CC(C(=O)O)C2)=C3C)c(OC)c1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 87
Group description: Subjects who were administered with ONO-4641 at a dose of 0.10 mg in the core study were administered with ONO-4641 at a dose of 0.10 mg once daily in the extension study for a duration of 225 weeks.
Eligibility criteria:
Inclusion Criteria:

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Exclusion Criteria:

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer
Intervention: Ceralifimod
Trial phase: Phase 2
SMILES: CCCc1ccc(COc2ccc3c(c2)CCC(CN2CC(C(=O)O)C2)=C3C)c(OC)c1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 89
Group description: Subjects who were administered with ONO-4641 at a dose of 0.05 mg in the core study were administered with ONO-4641 at a dose of 0.05 mg once daily in the extension study for a duration of 225 weeks.
Eligibility criteria:
Inclusion Criteria:

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Exclusion Criteria:

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer
Intervention: Ceralifimod
Trial phase: Phase 2
SMILES: CCCc1ccc(COc2ccc3c(c2)CCC(CN2CC(C(=O)O)C2)=C3C)c(OC)c1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Subjects who were administered with placebo in the core study were administered with ONO-4641 at a dose of 0.15 mg once daily in the extension study for a duration of 225 weeks.
Eligibility criteria:
Inclusion Criteria:

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Exclusion Criteria:

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer
Intervention: Ceralifimod
Trial phase: Phase 2
SMILES: CCCc1ccc(COc2ccc3c(c2)CCC(CN2CC(C(=O)O)C2)=C3C)c(OC)c1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Subjects who were administered with placebo in the core study were administered with ONO-4641 at a dose of 0.10 mg once daily in the extension study for a duration of 225 weeks.
Eligibility criteria:
Inclusion Criteria:

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Exclusion Criteria:

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer
Intervention: Ceralifimod
Trial phase: Phase 2
SMILES: CCCc1ccc(COc2ccc3c(c2)CCC(CN2CC(C(=O)O)C2)=C3C)c(OC)c1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Subjects who were administered with placebo in the core study were administered with ONO-4641 at a dose of 0.05 mg once daily in the extension study for a duration of 225 weeks.
Eligibility criteria:
Inclusion Criteria:

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Exclusion Criteria:

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer
Intervention: N-[2-[(3S)-3-[[4-hydroxy-4-(5-pyrimidin-2-ylpyridin-2-yl)cyclohexyl]amino]pyrrolidin-1-yl]-2-oxoethyl]-3-(trifluoromethyl)benzamide
Trial phase: Phase 2
SMILES: O=C(NCC(=O)N1CCC(NC2CCC(O)(c3ccc(-c4ncccn4)cn3)CC2)C1)c1cccc(C(F)(F)F)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: PF-04136309 administered orally as four 125 mg capsules twice daily for up to 4 weeks.
Eligibility criteria:
Inclusion Criteria:

Chronic HCV infection
ALT >1.5 but <10 times upper limit of normal

Exclusion Criteria:

Decompensated or severe liver disease defined by one or more of the following criteria:

Prior liver biopsy showing cirrhosis.

International Normalized Ratio (INR) greater than or equal to 1.5.
Total bilirubin greater than or equal to 1.5X ULN, or >2X ULN for unconjugated bilirubin.
Serum albumin below normal.
ALT or aspartate aminotransferase (AST) >10 x ULN.
Evidence of portal hypertension including splenomegaly, ascites, encephalopathy, and/or esophageal varices.
Presence of human immunodeficiency virus (HIV).
Co-infection with hepatitis B virus (HBV).
Co-infection with Epstein Barr Virus (EBV) and/or Cytomegalovirus (CMV).
Intervention: Naltrexone
Trial phase: Phase 2 | Phase 3
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Naltrexone + Medical Management/Medication Coaching

Naltrexone: NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
Eligibility criteria:
Inclusion Criteria:

Be HIV-infected.
Currently be prescribed HAART medication or be eligible to receive HAART medication.
Report less than 95% adherence to their HAART medication.
Report heavy drinking 4 or more times in the past 4 weeks, or meet current criteria for alcohol abuse or dependence. Heavy drinking is defined as 4 or more drinks for women and 5 or more drinks for men on one occasion.
Be at least 18 years old.
Be able to understand English and provide informed consent.

Exclusion Criteria:

Be psychotic or severely psychiatrically disabled.
Be currently enrolled in formal treatment for alcohol (excluding self-help, e.g. Alcoholics Anonymous)
Have medical conditions that would preclude completing or be of harm during the course of the study.
Have laboratory or clinical evidence of significant liver dysfunction (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of the normal range) or cirrhosis with a Child-Pugh classification greater than A or B.
Have a known contraindication to NTX therapy (e.g. requiring opioid medication for pain).

Be pregnant, nursing or unable to use an effective method of birth control (women).

-
Intervention: Warfarin
Trial phase: Phase 2
ATC code: B01AA03
SMILES: CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 70
Group description: Warfarin once daily
Eligibility criteria:
Inclusion criteria

Non-rheumatic atrial fibrillation.
Coronary artery disease (CAD), documented by previous myocard infarction (MI), angina, positive stress test, previous coronary intervention or bypass surgery, or atherosclerotic lesion(s) diagnosed by coronary angiography) is only considered as one of several possible qualifying risk factors. After recruitment of ca. 30%, a protocol amendment 4 was issued so that CAD was only considered as one of several possible qualifying risk factors, 2. see (3 f) below.

An additional risk factor for stroke, i.e. one or more of the following conditions/events:

hypertension (defined as systolic bloodpressure (SBP) > 140 mmHg and/or diastolic bloodpressure (DBP) > 90 mm Hg) requiring antihypertensive medical treatment.
diabetes mellitus (type I and II).
symptomatic heart failure or left ventricular dysfunction (ejection fraction (EF) < 40%).
a previous ischemic stroke or transient ischemic attack.
age greater than 75 years.
history of coronary artery disease (by amendment 4)
Treatment with warfarin or other vitamin K dependent anticoagulants for at least 8 weeks prior to inclusion. International normalised ratio (INR) should be within therapeutic range (i.e. INR 2.0 - 3.0) at visit 1 otherwise the visit should be rescheduled.
Age > = 18 years at entry.
Written, informed consent.

Exclusion criteria

Valvular heart disease.
Planned cardioversion.
Recent (=< 1 month) myocardial infarction, stroke or transient ischemic attack (TIA), or patients who have received a coronary stent within the last 6 months.
Intolerance or contraindications to acetylsalicylic acid (ASA).
Any contraindication to anticoagulant therapy.
Major bleeding within the last 6 months (other than gastrointestinal (GI) hemorrhage).
Severe renal impairment (estimated glomerular filtration rate (GFR) =< 30 mL/min).
Uncontrolled hypertension (SBP > 180 mmHg and/or DBP > 100 mmHg).
Abnormal liver function as defined by aspartat-aminotransferase (AST), alanin-aminotransferase (ALT), serum bilirubin or alkaline phosphatase (AP) above the reference range, or history of liver disease.
Women who are pregnant or of childbearing potential who refuses to use a medically acceptable form of contraception throughout the study.
Patients who have received an investigational drug within the last 30 days.
Patients scheduled for major surgery or invasive procedures which may cause bleeding, or those who have had major surgery or percutaneous coronary intervention (PCI) within 6 weeks.
Patients considered unreliable by the investigator.
Another indication for anticoagulant treatment.
Patients suffering from anemia.
Patients suffering from thrombocytopenia.
Any other condition which, in the discretion of the investigator, would not allow safe participation in the study.
Concomitant treatment with antiplatelet agents other than ASA.
Recent malignancy or radiation therapy (=< 6 month).
Intervention: Varenicline
Trial phase: Phase 4
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 218
Group description: Varenicline

Varenicline: Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
Eligibility criteria:
Inclusion Criteria:

18 yrs to 55 yrs
smoker

Exclusion Criteria:

Medical Contraindications
Intervention: Allopurinol
Trial phase: Not Applicable
ATC code: M04AA01 | M04AA51
SMILES: Oc1ncnc2[nH]ncc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.

Allopurinol: Xanthine oxidase inhibitor- effective at lowering uric acid levels.
Eligibility criteria:
Inclusion Criteria:

Individuals with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates between 30-60 mL/min/ 1.73m2
Elevated uric acid levels
Age range: more than 18 years old
Ability to give informed consent
Albumin > 3.0 g/dL
BMI < 40 kg/m2

Exclusion Criteria:

Life expectancy < 1.0 years
Expected to undergo living related kidney transplant in 6 months
Pregnant, breast feeding, or unwilling to use adequate birth control
History of severe liver disease
History of severe congestive heart failure
History of hospitalizations within 3 months
Active infection, on antibiotics
History of Warfarin Use or other medications that are contraindicated with allopurinol
Uncontrolled hypertension
History of acute gout on Allopurinol
History of adverse reaction to Allopurinol
Immunosuppressive therapy within the last 1 yr
Intervention: Bimatoprost
Trial phase: Phase 4
ATC code: S01EE03
SMILES: CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 62
Group description: bimatoprost 0.03% (LATISSE®)
Eligibility criteria:
Inclusion Criteria:

Eyelash prominence assessment of minimal or moderate
Of Korean ethnicity

Exclusion Criteria:

Any eye disease or abnormality
Any ocular surgery or use of any eyelash extension or eyelash growth products within 3 months
Any permanent eyeliner within 5 years
Eyelash implants of any kind
Eyelash tint or dye application within 2 months
Use of any treatment that may affect hair growth within 6 months
Intervention: Ibuprofen
Trial phase: Phase 3
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 169
Group description: Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®) by mouth
Eligibility criteria:
Main Inclusion Criteria:

Experiencing moderate to severe pain after extraction of impacted third molars

Main Exclusion Criteria:

Any ongoing painful condition other than that associated with the current third molar surgery that could significantly interfere with the subject's suitability Any condition that would render the subject unsuitable to receive an NSAID, acetaminophen or codeine
Intervention: Mapracorat
Trial phase: Phase 3
SMILES: Cc1ccc2c(NC[C@](O)(CC(C)(C)c3cc(F)cc4c3OCC4)C(F)(F)F)cccc2n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 207
Group description: Ophthalmic suspension 3%

Mapracorat: Instill study medication into study eye per dosing instructions for 14 days
Eligibility criteria:
Inclusion Criteria:

Participants who are candidates for routine, uncomplicated cataract surgery
Participants who, in the Investigator's opinion, have potential postoperative pinhole Snellen visual acuity (VA) of at least 20/200 in the study eye.
Participants must be willing to wait to undergo cataract surgery on the fellow eye until after the study has been completed.

Exclusion Criteria:

Participants who are expected to require concurrent ocular therapy (either eye) with nonsteroidal anti-inflammatory drugs (NSAIDs), mast cell stabilizers, antihistamines, or decongestants.
Participants who are expected to require treatment with any systemic or ocular (either eye) corticosteroids or glucocorticoids.
Participants who are expected to require concurrent ocular therapy with immunosuppressants (eg, Restasis).
Participants who have known hypersensitivity or contraindication to the study drug(s) or their components.
Participants participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.
Intervention: Cholecalciferol
Trial phase: Phase 4
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months

Vitamin D3: Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
Eligibility criteria:
Inclusion Criteria:

HF patients with LV systolic dysfunction of ischemic or non-ischemic origin and an LVEF <40% using nuclear ventriculography or echocardiography within the last 6 months.
Attempts should have been made at optimizing medical therapy and the participant should be stable on these medications for at least 3 months.
Patients with a 25(OH)D level between 10-25 ng/ml

Exclusion Criteria:

Inability to give informed consent
Patients with sarcoidosis or other granulomatous disease that can alter vitamin D metabolism
Patients with primary valvular HF, hypertrophic cardiomyopathy, and drug-induced HF
Renal dysfunction defined as serum creatinine > 2.5 mg/dl
Pregnant women
Patients <18 years of age
Patients on vitamin D supplementation